Molecular motor-type modified collagen-elastin peptide composition with high transdermal efficiency and its application
A self-driven bilayer structure was prepared by combining collagen peptides and elastin peptides in a specific ratio, which solved the problem of large molecular protein drugs penetrating the skin barrier, achieved rapid delivery and enhanced transdermal drug delivery, and also has antioxidant and fibroblast-promoting functions.
Patent Information
- Application Number
- CN202210646674.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-06-09
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2042-06-09
AI Technical Summary
Existing technologies are insufficient to effectively penetrate the skin barrier to deliver large-molecule protein drugs into the body. Conductivity enhancers are short-acting, easily metabolized, and have skin toxicity. Physical methods rely on equipment and are difficult to apply on a large scale.
A composition with a bilayer structure was prepared by mixing, homogenizing, filtering, and heating collagen peptides, elastin peptides, palmitoyl collagen peptides, glycerol, and glyceroglucoside in a specific ratio, and utilizing its polarity changes in different media to self-drive skin penetration.
It achieves rapid penetration of the skin barrier, effectively delivers macromolecular protein drugs, enhances transdermal drug delivery, and also has antioxidant and fibroblast-promoting functions.
Smart Images

Figure CN115040631B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of biological preparation production, and specifically relates to a molecular motor type modified collagen-elastin peptide composition with high transdermal efficiency and application thereof. Background Art
[0002] The transdermal drug delivery system is a new drug delivery system, which refers to a new dosage form that delivers drugs on the skin surface, where the drugs penetrate the skin layers at a certain rate, enter the human body's systemic blood circulation through the capillaries to reach effective blood drug concentrations, and achieve systemic or local therapeutic effects. Compared with oral and intravenous administration, transdermal drug delivery has the advantages of avoiding the first-pass effect of the liver and gastrointestinal tract, reducing fluctuations in blood drug concentrations, avoiding drug irritation to the gastrointestinal tract, non-invasive drug delivery, and strong compliance, because drug absorption is not affected by factors such as pH, food, and transit time in the digestive tract. Due to its more humane drug delivery and treatment characteristics and the continuous development of transdermal technology, it has become one of the fastest-growing fields in the pharmaceutical industry.
[0003] Human skin is divided into epidermis, dermis and subcutaneous tissue. The epidermis is covered by a stratum corneum composed of dead cells. The function of the stratum corneum is to protect the skin physically, mechanically, chemically and biologically, and can block the entry of most macromolecular substances, protect it from damage by harmful substances, and maintain the integrity of its functions. However, the stratum corneum barrier also prevents the epidermis and dermis from absorbing exogenous nutrients and drugs supplied through the epidermis.
[0004] Transdermal penetration enhancers refer to compounds that can accelerate the penetration of topical drugs through the skin, such as pyrrolidone, azone, alcohols, amino acid lipids, etc. However, there is no completely ideal transdermal penetration enhancer to date. On the one hand, existing transdermal penetration enhancer compounds have a short duration and are easily metabolized; on the other hand, the transdermal effect is not ideal and has skin toxicity at high concentrations. In particular, they have almost no effect on the transdermal penetration of biological macromolecules such as proteins.
[0005] Because macromolecular proteins and peptide drugs are both hydrophilic macromolecules, they can hardly penetrate the lipophilic barrier of the stratum corneum of the skin. Even with the help of transdermal penetration enhancers, protein molecules with large molecular weights find it difficult to penetrate the stratum corneum. Coupled with the impermeability of the epidermis, the transdermal delivery of bioactive macromolecular protein substances has not been solved for a long time. How to enable valuable biomacromolecules to be delivered through the epidermis has become a difficult and hot topic in research. There is a wide range of studies on the use of physical methods to mediate protein transdermal delivery, including ultrasound, electric shock, microneedles and other methods, but due to its dependence on equipment, it is difficult to be applied on a large scale. Summary of the invention
[0006] The object of the present invention is to provide a molecular motor-type modified collagen-elastin peptide composition with high transdermal efficiency.
[0007] Another object of the present invention is to provide application of the above composition.
[0008] According to a specific embodiment of the present invention, the molecular motor-type modified collagen-elastin peptide composition with high transdermal efficiency comprises the following raw materials by mass percentage: 0.3-1.4% collagen peptide, 0.2-1.2% elastin peptide, 0.05-0.2% palmitoyl collagen peptide, 0.8-1.3% glycerol, 0.7-1.5% glycerol glucoside, and the balance is water.
[0009] The composition is prepared by a preparation method comprising the following steps:
[0010] S1. Weigh glycerol, glycerol glucoside and water in proportion and mix them evenly;
[0011] S2, adding collagen peptide and elastin peptide to the mixture obtained in step S1, and stirring at 10-40° C. until dissolved;
[0012] S3, adding palmitoyl collagen peptide to the mixture obtained in step S2 and mixing evenly;
[0013] S4, homogenizing the solution obtained in step S3 at a speed of 1000-8000 r / min for 2-20 min;
[0014] S5, filtering the homogenized solution;
[0015] S6. The liquid obtained in step S5 is heated to 120° C., incubated for 20-40 minutes, and cooled to room temperature to obtain the composition.
[0016] The present invention selects collagen peptides, elastin peptides, palmitoyl collagen peptides, glycerol, and glycerol glucoside, limits the above raw materials to specific proportions, and obtains the molecular motor-type modified collagen-elastin peptide composition with high transdermal efficiency of the present invention through gradual mixing, homogenization, filtration, incubation and other steps.
[0017] The composition obtained by the above components and methods is a new type of spherical or nearly spherical bilayer structure with amphiphilic properties. In the water phase system, the hydrophilic groups are outward and the lipophilic groups are inward. When entering the oil phase system, it will rearrange into a bilayer structure with the lipophilic groups outward and the hydrophilic groups inward when sensing the change in surface tension. It has faster and stronger transdermal performance and can quickly penetrate the cell membrane.
[0018] According to the molecular motor-type modified collagen-elastin peptide composition with high transdermal efficiency according to a specific embodiment of the present invention, the molecular weight range of the collagen peptide is 200-2000 Daltons, preferably, the molecular weight range of the collagen peptide is 200-1000 Daltons, and more preferably, the molecular weight range of the collagen peptide is 500-1000 Daltons.
[0019] According to the molecular motor-type modified collagen-elastin peptide composition with high transdermal efficiency in a specific embodiment of the present invention, the collagen peptide is selected from one or more of fish skin collagen peptide, fish bone collagen peptide and fish scale collagen peptide.
[0020] According to the molecular motor type modified collagen-elastin peptide composition with high transdermal efficiency according to a specific embodiment of the present invention, the molecular weight range of the elastin peptide is 200-5000 Daltons, preferably, the molecular weight range of the elastin peptide is 200-1500 Daltons, and more preferably, the molecular weight range of the elastin peptide is 500-1000 Daltons.
[0021] According to the molecular motor-type modified collagen-elastin peptide composition with high transdermal efficiency in a specific embodiment of the present invention, the elastin peptide is selected from one or more of bovine cardiovascular elastin peptide, bovine ligament elastin peptide, and fish cardiovascular elastin peptide.
[0022] According to the molecular motor-type modified collagen-elastin peptide composition with high transdermal efficiency according to a specific embodiment of the present invention, the molecular weight range of the palmitoyl collagen peptide is 200-1500 Daltons, preferably, the molecular weight range of the palmitoyl collagen peptide is 200-1200 Daltons, and more preferably, the molecular weight range of the palmitoyl collagen peptide is 300-1000 Daltons.
[0023] According to the molecular motor-type modified collagen-elastin peptide composition with high transdermal efficiency in a specific embodiment of the present invention, in step S5, the homogenized solution is filtered using a 0.22 micron filter membrane.
[0024] The molecular motor-type modified collagen-elastin peptide composition with high transdermal efficiency of the present invention can be applied to transdermal drug delivery systems, especially drugs absorbed through transdermal delivery, or cosmetic preparations.
[0025] The composition of the present invention can be used as a main raw material to prepare a medicine using a pharmaceutically acceptable carrier. The medicine can be a liquid, a gel, a gel, a paste, a patch, or a foam. The medicine can be used in vitro, especially for external use on the skin.
[0026] The composition of the present invention can be used as a main raw material to prepare medical devices. Medical devices refer to materials and other similar or related items that are directly or indirectly used on the human body. The medical device can be a liquid, a gel, a gel, a paste, a patch, or a foam. The medical device can be used in vitro, and in particular can be used externally on the skin.
[0027] The composition of the present invention can be used as the main raw material to prepare cosmetics using auxiliary materials acceptable in the cosmetics field. The cosmetics can be liquid, gel, gel, paste, patch, foam. The cosmetics can be used in vitro, especially for external use on the skin.
[0028] Beneficial effects of the present invention:
[0029] The composition of the present invention is a spherical or nearly spherical bilayer structure with amphiphilic properties. It can self-drive to change its own morphology based on changes in surface tension, and can quickly penetrate the skin barrier and cell membrane by utilizing the principle of similar polarity dissolving each other through morphological changes. It has the ability to quickly penetrate the skin and can pass through the stratum corneum of the skin and enter the cells in the epidermis and dermis.
[0030] At the same time, the composition of the present invention contains abundant functional groups such as amino and carboxyl groups, which can combine with protein active macromolecules through intermolecular forces to achieve drug delivery through the skin and cell membrane, thereby achieving the purpose of transdermal drug delivery and improving the effect of transdermal drug delivery.
[0031] The composition of the invention contains ingredients such as collagen peptides and elastin peptides, and has the functions of anti-oxidation, inhibiting matrix metalloproteinases, and improving fibroblast activity. BRIEF DESCRIPTION OF THE DRAWINGS
[0032] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0033] Figure 1 The laser confocal microscopy test results of the compositions prepared in Example 3 and Comparative Example 1 are shown, wherein A-Comparative Example 1; B-Comparative Example 2; C-Example 3; D-Comparative Example 3;
[0034] Figure 2The effect of the composition of the present invention on improving the viability of fibroblasts was shown; wherein the blank control was cultured in normal RPMI-1640 culture medium; the UA-control was fibroblasts irradiated with ultraviolet light; the sample was fibroblasts cultured with the addition of a molecular motor-type modified collagen-elastin peptide solution; the UA-sample was fibroblasts cultured with the addition of a molecular motor-type modified collagen-elastin peptide solution after ultraviolet irradiation;
[0035] Figure 3 The confocal microscope detection results of the mouse transdermal experiment of the compositions prepared in Example 3 and Comparative Example 1 are shown, A-Comparative Example 1; B-Example 3. DETAILED DESCRIPTION
[0036] To make the purpose, technical solution and advantages of the present invention clearer, the technical solution of the present invention will be described in detail below. Obviously, the described embodiments are only part of the embodiments of the present invention, rather than all the embodiments. Based on the embodiments of the present invention, all other implementation methods obtained by ordinary technicians in this field without creative work belong to the scope of protection of the present invention.
[0037] The raw materials used in the embodiments of the present invention, such as collagen peptides, elastin peptides, and palmitoyl collagen peptides, are all commercially available products.
[0038] The molecular motor type modified collagen-elastin peptide composition with high transdermal efficiency of the present invention comprises the following raw materials by mass percentage: 0.3-1.4% collagen peptide, 0.2-1.2% elastin peptide, 0.05-0.2% palmitoyl collagen peptide, 0.8-1.3% glycerol, 0.7-1.5% glycerol glucoside, and the balance is water.
[0039] The composition is prepared by a method comprising the following steps:
[0040] S1. Weigh glycerol, glycerol glucoside and water in proportion and mix them evenly;
[0041] S2, adding collagen peptide and elastin peptide to the mixture obtained in step S1, and stirring at 10-40° C. until dissolved;
[0042] S3, adding palmitoyl collagen peptide to the mixture obtained in step S2 and mixing evenly;
[0043] S4, homogenizing the solution obtained in step S3 at a speed of 1000-8000 r / min for 2-20 min;
[0044] S5, filtering the homogenized solution;
[0045] S6. The liquid obtained in step S5 is heated to 120° C., incubated for 20-40 minutes, and cooled to room temperature to obtain the composition.
[0046] The present invention is specifically described by the following examples:
[0047] Example 1
[0048] The modified highly transdermal collagen peptide composition of the present invention contains the following components in percentage by mass based on 1000 g: 0.38% of cod skin collagen peptide (molecular weight range 200-1000 Daltons), 0.61% of bovine ligament elastin peptide (molecular weight range 200-1000 Daltons), 0.05% of palmitoyl collagen peptide (molecular weight range 200-1000 Daltons), 1.0% of glycerol, 1.0% of glycerol glucoside, and the balance of water.
[0049] The preparation method is as follows:
[0050] S1. Mix glycerol, glycerol glucoside and water evenly;
[0051] S2. Add collagen peptide and elastin peptide to the solution obtained in S1 in sequence, and stir at 25° C. for 10 minutes until all of them are dissolved;
[0052] S3, adding palmitoyl collagen peptide to the solution obtained in S2, and stirring at 25°C for 10 minutes until it is completely dissolved;
[0053] S4, homogenizing the solution obtained in step S3 at a speed of 8000 r / min for 5 min;
[0054] S5, filtering the homogenized solution through a 0.22 μm filter membrane;
[0055] S6. The liquid obtained in step S5 is heated to 120° C. and incubated for 20 minutes, and then cooled to room temperature to obtain the composition of the present invention.
[0056] Example 2
[0057] The modified high transdermal collagen peptide composition of the present invention contains the following components in percentage by mass based on 1000 g: 0.62% of cod skin collagen peptide (molecular weight range 200-1000 Daltons), 1.20% of bovine ligament elastin peptide (molecular weight range 200-1000 Daltons), 0.1% of palmitoyl collagen peptide (molecular weight range 200-1000 Daltons), 1.0% of glycerol, 1.0% of glycerol glucoside, and the balance of water.
[0058] The preparation method is as follows:
[0059] S1. Mix glycerol, glyceryl glucoside and water evenly;
[0060] S2, add collagen peptide and elastin peptide to the solution obtained in S1 in sequence, and stir at 25°C for 10 minutes until all of them are dissolved;
[0061] S3, adding palmitoyl collagen peptide to the solution obtained in S2, and stirring at 25°C for 10 minutes until it is completely dissolved;
[0062] S4, homogenizing the solution obtained in step S3 at a speed of 6000 r / min for 10 min;
[0063] S5, filtering the homogenized solution through a 0.22 μm filter membrane;
[0064] S6. The liquid obtained in step S5 is heated to 120° C. and incubated for 30 minutes, and then cooled to room temperature to obtain the composition of the present invention.
[0065] Example 3
[0066] The modified highly transdermal collagen peptide composition of the present invention contains the following components in percentage by mass based on 1000 g: 0.62% FITC-labeled cod skin collagen peptide (molecular weight range 200-1000 Daltons), 1.20% FITC-labeled bovine ligament elastin peptide (molecular weight range 200-1000 Daltons), 0.1% palmitoyl collagen peptide (molecular weight range 200-1000 Daltons), 1.0% glycerol, 1.0% glycerol glucoside, and the balance is water.
[0067] The preparation method is as follows:
[0068] S1. Mix glycerol, glycerol glucoside and water evenly;
[0069] S2, add collagen peptide and elastin peptide to the solution obtained in S1 in sequence, and stir at 25°C for 10 minutes until all of them are dissolved;
[0070] S3, adding palmitoyl collagen peptide to the solution obtained in S2, and stirring at 25°C for 10 minutes until it is completely dissolved;
[0071] S4, homogenizing the solution obtained in step S3 at a speed of 6000 r / min for 10 min;
[0072] S5, filtering the homogenized solution through a 0.22 μm filter membrane;
[0073] S6. The liquid obtained in step S5 is heated to 120° C. and incubated for 30 minutes, and then cooled to room temperature to obtain the system.
[0074] Embodiment 4 effect test
[0075] 4.1 Influencing factors of the effect of the composition of the present invention
[0076] Comparative Example 1: Compared with Example 3, the preparation method is to mix the components, specifically:
[0077] In terms of mass percentage, it is composed of the following components: FITC-labeled cod skin collagen peptide (molecular weight range 200-1000 Daltons) 0.62%, FITC-labeled bovine ligament elastin peptide (molecular weight range 200-1000 Daltons) 1.20%, palmitoyl collagen peptide (molecular weight range 200-1000 Daltons) 0.1%, glycerol 1.0%, glycerol glucoside 1.0%, and the balance is water. Prepared according to the following steps:
[0078] S1. Mix glycerol, glyceryl glucoside, water, collagen peptide, elastin peptide and palmitoyl collagen peptide evenly, and stir at 25°C for 10 minutes until all dissolved.
[0079] Comparative Example 2: Compared with Example 3, the components lack palmitoyl collagen peptide, specifically:
[0080] In terms of mass percentage, it is composed of the following components: FITC-labeled cod skin collagen peptide (molecular weight range 200-1000 Daltons) 2.0%, FITC-labeled bovine ligament elastin peptide (molecular weight range 200-1000 Daltons) 5.0%, glycerol 5.0%, glycerol glucoside 3.0%, and the balance is water. Prepared according to the following steps:
[0081] S1. Mix glycerol, glycerol glucoside and water evenly;
[0082] S2. Add collagen peptide and elastin peptide to the solution obtained in S1 in sequence, and stir at 25° C. for 10 minutes until all of them are dissolved;
[0083] S3, homogenizing the solution obtained in step S2 at a speed of 6000 r / min for 10 min;
[0084] S4, filtering the homogenized solution through a 0.22 μm filter membrane;
[0085] S5. Heat the liquid obtained in step S4 to 120° C., incubate for 30 minutes, and cool to room temperature.
[0086] Comparative Example 3: 1 ml of the liquid obtained in Example 3 was added to 5 ml of n-octanol and homogenized at a speed of 6000 r / min for 10 minutes.
[0087] The samples of Comparative Examples 1, 2, 3 and Example 3 were subjected to laser confocal detection.
[0088] The results are as follows Figure 1 As shown, it can be seen that when the preparation method is changed to a simple mixing of the components, the collagen peptides and elastin peptides are dispersed separately in the solution, and no aggregation occurs ( Figure 1 -A), when palmitoyl collagen peptide is missing in the components, it can be seen that collagen peptide and elastin peptide are dispersed separately in the solution, and no aggregation occurs ( Figure 1 -B).
[0089] The composition prepared by the inventive method is a spherical or nearly spherical bilayer structure, with the hydrophilic groups facing outward and the lipophilic groups facing inward ( Figure 1 -C), the liquid obtained in Comparative Example 3 was added to n-octanol, and it can be seen that the protein peptide is a spherical or nearly spherical bilayer structure, showing a morphology in which the hydrophilic groups are gathered inwards ( Figure 1 -D).
[0090] Therefore, the highly transdermal collagen peptide composition of the present invention needs to use collagen peptide, elastin peptide, palmitoyl collagen peptide, glycerol, glycerol glucoside and other ingredients, and can be prepared under the operation of the specific steps of the present invention.
[0091] 4.2 Investigation of the effect of improving fibroblast viability
[0092] Cell culture conditions: Fibroblasts were seeded in 96-well plates at 1*10 4 Each group was replicated 4 times and cultured in different culture media at 37°C and 25% CO2.
[0093] Preparation conditions of photoaged fibroblasts: UVB dose was measured and calibrated using a UV photometer. The cells seeded in a 96-well plate were washed thoroughly with the prepared PBS, with 1*10 cells per well. 4 Then, ultraviolet irradiation (5J / cm 2 After the UV irradiation, the cells were washed again with PBS. After the cells were fully washed, they were cultured in culture medium.
[0094] The culture medium was replaced, blank control group: cultured with RPMI-1640 complete medium; UV-control group sample group: the fibroblasts treated with UV were cultured with RPMI-1640 complete medium; sample group: cultured with RPMI-1640 complete medium containing 200ug / mL of the solution obtained in Example 3; UV-sample group: the fibroblasts treated with UV were cultured with RPMI-1640 complete medium containing 200ug / mL of the solution obtained in Example 3, with 4 replicates in each group.
[0095] After the cells were cultured for a certain period of time, 10uL of CCK-8 detection kit solution was added to each well, the culture plate was incubated in an incubator for 3h, and then the absorbance (OD) value at 450nm was detected using an enzyme reader.
[0096] The cell proliferation rate (D%) was calculated according to the following formula: (OD 样品组 -OD 阴性对照组 ) / (OD 空白对照组 -OD 阴性对照组 ), and the OD value was used to indicate the amount of living cells.
[0097] Test results see Figure 2 Compared with the blank control, the proliferation rate of the fibroblast group mixed with the molecular motor-type modified collagen-elastin peptide solution was significantly higher than that of the blank control group. The proliferation rate of the fibroblast group mixed with the molecular motor-type modified collagen-elastin peptide solution after UV treatment was significantly higher than that of the UV irradiation control group, P < 0.05, with significant differences.
[0098] 4.3 Investigation of transdermal absorption effect
[0099] The liquid obtained in Example 3 and Comparative Example 1 was added with water to prepare a solution with a concentration of 25 ml / L, and evenly applied to the back of the mouse after shaving, once every 30 minutes, for a total of 5 times. The skin on the back of the mouse was cut, fixed in a tissue fixative, embedded in paraffin, and sliced longitudinally, and kept away from light throughout the process.
[0100] After dewaxing, the tissue sections were photographed using a laser confocal microscope with an excitation wavelength of 460-550 nm and an emission wavelength of 520-530 nm.
[0101] The results are as follows Figure 3 As shown, compared with the blank control ( Figure 3 -A) Compared with Figure 3 -B shows that the entire skin from the epidermis to the dermis has an obvious fluorescent reaction, indicating that the modified collagen-elastin peptide system penetrates the skin quickly and can penetrate into the dermis.
[0102] The above is only a specific embodiment of the present invention, but the protection scope of the present invention is not limited thereto. Any person skilled in the art can easily think of changes or substitutions within the technical scope disclosed by the present invention, which should be included in the protection scope of the present invention. Therefore, the protection scope of the present invention should be based on the protection scope of the claims.
Claims
1. A molecular motor-type modified collagen-elastin peptide composition with high transdermal efficiency, characterized in that: The composition comprises the following raw materials in percentage by mass: 0.38-0.62% collagen peptide, 0.61-1.2% elastin peptide, 0.05-0.1% palmitoyl collagen peptide, 1.0% glycerol, 1.0% glycerol glucoside, and the balance is water. The molecular weight of the collagen peptide ranges from 200 to 1000 Daltons; The molecular weight of the elastin peptide ranges from 200 to 1000 Daltons; The molecular weight of the palmitoyl collagen peptide ranges from 200 to 1000 Daltons; The composition is prepared by a method comprising the following steps: S1. Weigh glycerol, glycerol glucoside and water in proportion and mix them evenly; S2, adding collagen peptide and elastin peptide to the mixture obtained in step S1, and stirring at 25° C. until dissolved; S3, adding palmitoyl collagen peptide to the mixture obtained in step S2 and mixing evenly; S4, homogenizing the solution obtained in step S3 at a speed of 6000-8000 r / min for 5-10 min; S5, filtering the homogenized solution; S6, heating the liquid obtained in step S5 to 120° C., incubating for 20-30 minutes, and cooling to room temperature to obtain the composition; The collagen peptide is selected from one or more of fish skin collagen peptide, fish bone collagen peptide, and fish scale collagen peptide; The elastin peptide is selected from one or more of bovine cardiovascular elastin peptide, bovine ligament elastin peptide, and fish cardiovascular elastin peptide.
2. The molecular motor-type modified collagen-elastin peptide composition with high transdermal efficiency according to claim 1, characterized in that: In step S5, the homogenized solution is filtered using a 0.22 μm filter membrane.
3. Use of the molecular motor-type modified collagen-elastin peptide composition with high transdermal efficiency according to claim 1 in the preparation of cosmetic preparations.
